Genome analysis of esophageal cancer by next generation sequencer aiming for appropriately-individualized treatment

2016 Fiscal Year Final Research Report

• Project/Area Number: 26462001
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: Chiba Cancer Center (Research Institute)
• Principal Investigator: NABEYA Yoshihiro 千葉県がんセンター(研究所), 食道・胃腸外科, 部長 (40322028)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 食道がん / ゲノム / 次世代シークエンサー / 腫瘍マーカー

Outline of Final Research Achievements

To identify some useful biomarker for early diagnosis of esophageal cancer (EC), we have conducted exome analysis limited to the regions where mutations are found frequently in cancer, in the EC and the corresponding noncancerous tissues as well as in the cohort of gastroenterological cancer patients and healthy volunteers. Four of the 21 gene mutations confirmed in the EC with the next generation sequencer were also confirmed in the non-cancerous tissues as well. Furthermore, 5 genes that could affect the structure and function of the protein were confirmed. These findings suggest the concept of Mutation Signature may be useful as a biomarker of EC. Evaluating the clinical courses of EC surgical cases revealed that serum SCC-Ag monitoring may be useful as a prognostic indicator. Assessment of these potential biomarkers are expected to help the early diagnosis and individualized treatment of EC, to which surgical treatment is invasive, followed by improvement of the outcome.

Free Research Field

消化器外科学